Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313383648> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4313383648 endingPage "58.18" @default.
- W4313383648 startingPage "58.18" @default.
- W4313383648 abstract "Abstract Combination immunotherapy with bispecific abs, linked scFv’s or T cell engagers have not shown that both checkpoint blockade and TNF receptor activation can be achieved with a single molecule, likely due to a loss of target avidity. Fusion proteins incorporating the extracellular domain of type I membrane proteins (eg. Enbrel) or type II membrane proteins (eg. SIRPα-Fc), linked via an antibody Fc domain, are both functional despite the ECDs being in opposite orientation. We report the generation of a two-sided fusion protein (ARC) incorporating the ECD of SIRPα (CD172a) and the ECD of CD40L, adjoined by a central Fc domain. The SIRPα end of the ARC binds CD47 at 3.59 nM affinity, but does not cause hemolysis, compared to CD47 mAbs. The CD40L end binds CD40 at 756 pM affinity and binds CD40 on primary macrophages. The SIRPα-Fc-CD40L ARC stimulates NFκB-functional activity (independent of Fc receptor cross-linking) and IL2 and TNFα secretion in an ex vivo super-antigen (SEB) assay. Furthermore, live cell imaging shows that SIRPα-Fc-CD40L enhanced phagocytosis of tumor cells by primary macrophages. Finally, the therapeutic activity of SIRPα-Fc-CD40L in established murine MC38 and CT26 tumors was superior to either CD47 blocking antibody, CD40 agonist antibody or their combination. Finally, treatment of cynomolgus macaques with SIRPα-Fc-CD40L was safe, and no evidence of hemolysis or thrombocytopenia was observed. These data demonstrate feasibility of a novel chimeric fusion protein platform, providing checkpoint blockade and TNF superfamily costimulation in a single molecule, which may uniquely poise macrophages in the TME for activation and cross-presentation of tumor antigens following enhanced tumor cell phagocytosis." @default.
- W4313383648 created "2023-01-06" @default.
- W4313383648 creator A5001670202 @default.
- W4313383648 creator A5016340598 @default.
- W4313383648 creator A5033794726 @default.
- W4313383648 creator A5063908914 @default.
- W4313383648 creator A5087439323 @default.
- W4313383648 creator A5090011898 @default.
- W4313383648 date "2018-05-01" @default.
- W4313383648 modified "2023-09-30" @default.
- W4313383648 title "Agonist Redirected Checkpoint (ARC), SIRPα-Fc-CD40L, for Cancer Immunotherapy" @default.
- W4313383648 doi "https://doi.org/10.4049/jimmunol.200.supp.58.18" @default.
- W4313383648 hasPublicationYear "2018" @default.
- W4313383648 type Work @default.
- W4313383648 citedByCount "0" @default.
- W4313383648 crossrefType "journal-article" @default.
- W4313383648 hasAuthorship W4313383648A5001670202 @default.
- W4313383648 hasAuthorship W4313383648A5016340598 @default.
- W4313383648 hasAuthorship W4313383648A5033794726 @default.
- W4313383648 hasAuthorship W4313383648A5063908914 @default.
- W4313383648 hasAuthorship W4313383648A5087439323 @default.
- W4313383648 hasAuthorship W4313383648A5090011898 @default.
- W4313383648 hasConcept C104317684 @default.
- W4313383648 hasConcept C123894998 @default.
- W4313383648 hasConcept C154317977 @default.
- W4313383648 hasConcept C159654299 @default.
- W4313383648 hasConcept C170493617 @default.
- W4313383648 hasConcept C185592680 @default.
- W4313383648 hasConcept C202751555 @default.
- W4313383648 hasConcept C203014093 @default.
- W4313383648 hasConcept C2777701055 @default.
- W4313383648 hasConcept C2779234475 @default.
- W4313383648 hasConcept C2779931124 @default.
- W4313383648 hasConcept C2780104668 @default.
- W4313383648 hasConcept C2780674031 @default.
- W4313383648 hasConcept C2780851360 @default.
- W4313383648 hasConcept C39347974 @default.
- W4313383648 hasConcept C40767141 @default.
- W4313383648 hasConcept C502942594 @default.
- W4313383648 hasConcept C55493867 @default.
- W4313383648 hasConcept C86803240 @default.
- W4313383648 hasConcept C8891405 @default.
- W4313383648 hasConcept C95444343 @default.
- W4313383648 hasConceptScore W4313383648C104317684 @default.
- W4313383648 hasConceptScore W4313383648C123894998 @default.
- W4313383648 hasConceptScore W4313383648C154317977 @default.
- W4313383648 hasConceptScore W4313383648C159654299 @default.
- W4313383648 hasConceptScore W4313383648C170493617 @default.
- W4313383648 hasConceptScore W4313383648C185592680 @default.
- W4313383648 hasConceptScore W4313383648C202751555 @default.
- W4313383648 hasConceptScore W4313383648C203014093 @default.
- W4313383648 hasConceptScore W4313383648C2777701055 @default.
- W4313383648 hasConceptScore W4313383648C2779234475 @default.
- W4313383648 hasConceptScore W4313383648C2779931124 @default.
- W4313383648 hasConceptScore W4313383648C2780104668 @default.
- W4313383648 hasConceptScore W4313383648C2780674031 @default.
- W4313383648 hasConceptScore W4313383648C2780851360 @default.
- W4313383648 hasConceptScore W4313383648C39347974 @default.
- W4313383648 hasConceptScore W4313383648C40767141 @default.
- W4313383648 hasConceptScore W4313383648C502942594 @default.
- W4313383648 hasConceptScore W4313383648C55493867 @default.
- W4313383648 hasConceptScore W4313383648C86803240 @default.
- W4313383648 hasConceptScore W4313383648C8891405 @default.
- W4313383648 hasConceptScore W4313383648C95444343 @default.
- W4313383648 hasIssue "1_Supplement" @default.
- W4313383648 hasLocation W43133836481 @default.
- W4313383648 hasOpenAccess W4313383648 @default.
- W4313383648 hasPrimaryLocation W43133836481 @default.
- W4313383648 hasRelatedWork W2801298049 @default.
- W4313383648 hasRelatedWork W2889258202 @default.
- W4313383648 hasRelatedWork W2953852303 @default.
- W4313383648 hasRelatedWork W3030368707 @default.
- W4313383648 hasRelatedWork W3034173713 @default.
- W4313383648 hasRelatedWork W3139077444 @default.
- W4313383648 hasRelatedWork W3174769180 @default.
- W4313383648 hasRelatedWork W4225811843 @default.
- W4313383648 hasRelatedWork W4303613753 @default.
- W4313383648 hasRelatedWork W4313383648 @default.
- W4313383648 hasVolume "200" @default.
- W4313383648 isParatext "false" @default.
- W4313383648 isRetracted "false" @default.
- W4313383648 workType "article" @default.